von Willebrand Factor (vWF) is a glycoprotein produced by bone marrow cells and endothelial cells lining the inside surface of blood vessels. Its primary function is platelet adhesion, binding to Factor VIII, collagen and platelets, to coagulate blood at the site of wounding. The enzyme VWFCP, or vWF-cleaving protease, facilitates clotting by cutting the protein into subunits, increasing its binding capacity.

Deficiency or dysfunction of the protein increases the tendency of wounds to bleed, or to bleed more.  Over 300 gene mutations have been identified and classified into three types.  Type 1 von Willebrand Factor disease is characterised by reduced amounts in the bloodstream, Type 2 by reduced binding ability and Type 3 by a nonfunctional protein.

Flow Cytometry: 0,5-1 µg/million cells IF: 0,5 - 1 µg/ml WB: 0,5-1,0 µg/ml IHC (FFPE): 0,5-1,0 µg/ml for 30 minutes at RT (1) Variations in protocols, secondaries and substrates may require the von Willebrand Factor antibody to be titered for optimal performance.

1. FFPE staining requires boiling tissue sections in 10 mM Citrate Buffer, pH 6,0, for 10 - 20 min followed by cooling at RT for 20 minutes.

Type: Primary
Antigen: VWF
Clonality: Monoclonal
Clone: VWF635
Conjugation: Unconjugated
Epitope:
Host: Mouse
Isotype: IgG1, kappa
Reactivity: Human